|Original language||English (US)|
|Number of pages||2|
|State||Published - Dec 7 2021|
ASJC Scopus subject areas
Access to Document
Other files and links
Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk - Reply. / Wilkins, John T.; Lloyd-Jones, Donald M.In: JAMA, Vol. 326, No. 21, 07.12.2021, p. 2205-2206.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk - Reply
AU - Wilkins, John T.
AU - Lloyd-Jones, Donald M.
N1 - Funding Information: Conflict of Interest Disclosures: Dr Wilkins reported receiving grants from the National Institutes of Health during the conduct of the study and consulting fees from NGM Biopharmaceuticals and 3M. Dr Lloyd-Jones reported receiving grants from the National Institutes of Health during the conduct of the study. Funding Information: Conflict of Interest Disclosures: Dr Ray reported receiving support from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre and that his institution (Imperial College London) receives support from the NIHR Applied Research Collaboration Northwest London. Dr Ray also reported receiving lecture fees from Kowa, Lupin, and Zuelling Pharma; grant support (paid to his institution), lecture fees, and advisory board fees from Amgen, Regeneron Pharmaceuticals/Sanofi, Daiichi Sankyo, and Pfizer; lecture fees and fees for serving on steering committees for trials from AstraZeneca and Eli Lilly; fees for serving on steering committees for trials from the Medicines Company and Esperion; advisory board fees from Abbott, Akcea Therapeutics, Novartis, Silence Therapeutics, Bayer, and Daiichi Sankyo; lecture fees and advisory board fees from Novo Nordisk and Boehringer Ingelheim; grant support and advisory board fees from Merck Sharp & Dohme; and fees for serving as principal investigator for a trial from Resverlogix. Dr Wright reported receiving advisory board fees from Boehringer Ingelheim and past fees for consulting on lipid issues from the Medicines Company. Funding/Support: Editorial support in the writing of this letter was funded by Novartis Pharma AG, Basel, Switzerland. Role of the Funder/Sponsor: Novartis Pharma AG had no role in the preparation of the manuscript or decision to submit the manuscript for publication. Novartis reviewed the manuscript (with no suggested changes) but did not have a right to reject the version submitted.
PY - 2021/12/7
Y1 - 2021/12/7
UR - http://www.scopus.com/inward/record.url?scp=85121231223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85121231223&partnerID=8YFLogxK
U2 - 10.1001/jama.2021.17980
DO - 10.1001/jama.2021.17980
M3 - Letter
C2 - 34874422
AN - SCOPUS:85121231223
SN - 0098-7484
VL - 326
SP - 2205
EP - 2206
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 21